Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine‐Needle Aspiration State of the Science Conference

By Zubair Baloch, V. Livolsi, S. Asa, J. Rosai, M. Merino, G. Randolph, P. Vielh, R. Demay, M. Sidawy, W. Frable. Diagnostic Cytopathology, 2008

862 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/c2796f95baa98b4b13fe2fca061c9a46ce5b98d9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Y. Nikiforov
2. M. Nikiforova

In Molecular Biology

1. Y. Nikiforov
2. M. Nikiforova

In Surgery

1. Y. Nikiforov
2. M. Nikiforova

Citations in the corpus

• The Bethesda System for Reporting Thyroid Cytopathology (2009, neutral): “Studies suggest, however, that follicular and Hürthle cell tumors have different underlying genetics (4,25).”
• Molecular genetics and diagnosis of thyroid cancer (2011, background): “The inability to rule out cancer in these nodules leads to diagnostic lobectomy for most of these patients, although 60–90% of the surgically removed thyroid nodules are found to be benign”
• Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. (2009, methodology): “In addition to a routine cytological evaluation of all FNA samples, cytology slides from 51 samples originally diagnosed as indeterminate were reviewed again by one cytopathologist (T.M.R.-S.) and classified into three categories as suggested by the National Cancer Institute Thyroid FNA State of the”
• Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer (2009, neutral): “The conference further recommended that ‘‘neoplasm, either follicular or Hürthle cell neoplasm’’ be substituted for ‘‘indeterminate’’ (risk of malignancy 15–25%) (42).”
• Hashimoto thyroiditis: clinical and diagnostic criteria. (2014, background): “Although the recommendation of the Bethesda system for this category is conservative management [71] and although most of these Hürthle cell lesions are benign [72], many patients are referred to a surgeon and often undergo thyroidectomy.”
• Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer (2015, methodology): “In adults, the risk of malignancy in indeterminate nodules ranges from *5% to 15% in the AUS/FLUS category to 15%–30% in the follicular neoplasm or suggestive of neoplasm group (122).”